Bourgonje et al. (24) recently reported that inflammatory biomarkers [serum amyloid A (SAA), Eotaxin-1, IL-6, IL-8, IL-17A, and TNF-α] showed better prediction of IBD disease activity than routine measures (CRP, fecal calprotectin, and HBI/SCCAI scores) and demonstrated that the combination of SAA, IL-6, IL-8, and Eotaxin-1 could reliably predict endoscopic disease activity in IBD, which contributed to establishing an immunology-based prediction model for the endoscopic mucosal status in IBD. This evidence concerns the gene IL6 and inflammatory bowel disease.